{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:11:57Z","timestamp":1791090717224,"version":"4.1.0"},"reference-count":193,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.canlet.2012.02.034","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T19:56:56Z","timestamp":1330977416000},"page":"18-34","source":"Crossref","is-referenced-by-count":44,"title":["Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies"],"prefix":"10.1016","volume":"322","author":[{"given":"Valerio","family":"Izzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Masuelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tresoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Modesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2012.02.034_b0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1378\/chest.103.4_Supplement.373S","article-title":"Natural history and epidemiology of malignant mesothelioma","volume":"103","author":"Antman","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.canlet.2012.02.034_b0970","series-title":"The Cancer Handbook","first-page":"767","article-title":"Pleura and peritoneum","author":"Fletcher","year":"2008"},{"key":"10.1016\/j.canlet.2012.02.034_b0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.1997.5460776.x","article-title":"Pathology of malignant mesothelioma","volume":"30","author":"Attanoos","year":"1997","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2012.02.034_b0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ajim.4700210214","article-title":"Possible cellular and molecular mechanisms for asbestos carcinogenicity","volume":"21","author":"Walker","year":"1992","journal-title":"Am. J. Indust. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.semdp.2006.08.002","article-title":"The pathogenesis of mesothelioma","volume":"23","author":"Carbone","year":"2006","journal-title":"Sem. Diagn. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2567.2006.02430.x","article-title":"Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity","volume":"119","author":"Kim","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2012.02.034_b0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000163784","article-title":"Pathogenesis of mesothelial reactions to asbestos fibers. Monocyte recruitment and macrophage activation","volume":"61","author":"Branchaud","year":"1993","journal-title":"Pathobiology"},{"key":"10.1016\/j.canlet.2012.02.034_b0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/08830180801939280","article-title":"Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules","volume":"27","author":"Bei","year":"2008","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0045","doi-asserted-by":"crossref","first-page":"746","DOI":"10.7326\/0003-4819-96-6-746","article-title":"Diffuse malignant mesothelioma: prospective evaluation of 69 patients","volume":"96","author":"Chahinian","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0050","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0055","first-page":"1781","article-title":"Simian virus 40-like DNA sequences in human pleural mesothelioma","volume":"9","author":"Carbone","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.02.034_b0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/(SICI)1096-9896(199604)178:4<369::AID-PATH460>3.0.CO;2-8","article-title":"Molecular pathobiology and immunology of malignant mesothelioma","volume":"178","author":"Bielefeldt-Ohmann","year":"1996","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0065","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1183\/09031936.95.08040643","article-title":"Biological and immunological aspects of malignant mesothelioma","volume":"8","author":"Garlepp","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.canlet.2012.02.034_b0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000113629","article-title":"Pathophysiology of the Pleura","volume":"75","author":"Jantz","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.canlet.2012.02.034_b0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jss.2006.10.012","article-title":"Surgery-derived reactive oxygen species produced by polymorphonuclear leukocytes promote tumor recurrence. Studies in an in vitro model","volume":"140","author":"van Grevenstein","year":"2007","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0006-8993(01)02688-9","article-title":"Superoxide-induced nitric oxide release from cultured glial cells","volume":"911","author":"Manning","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0891-5849(94)00149-E","article-title":"Neutrophil and asbestos fiber-induced cytotoxicity in cultured human mesothelial and bronchial epithelial cells","volume":"18","author":"Kinnula","year":"1995","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0090","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0278-6915(86)90157-2","article-title":"Influence of phagocyte-derived active oxygen species in tissue responses to tumor promoters and irritants","volume":"24","author":"Phillips","year":"1986","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.canlet.2012.02.034_b0095","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1289\/ehp.97105s51257","article-title":"Pleural macrophage recruitment and activation in asbestos-induced pleural injury","volume":"105","author":"Choe","year":"1997","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.canlet.2012.02.034_b0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1172\/JCI3169","article-title":"Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat","volume":"102","author":"Tanaka","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.02.034_b0105","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jlb.58.5.616","article-title":"Nitric oxide synthase in circulating vs. extravasated polymorphonuclear leukocytes","volume":"58","author":"Miles","year":"1995","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0110","first-page":"3696","article-title":"Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor","volume":"60","author":"Marrogi","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0115","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1681\/ASN.V11101848","article-title":"Expression of endothelial nitric oxide synthase in human peritoneal tissue: regulation by Escherichia coli lipopolysaccharide","volume":"11","author":"Arriero","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.canlet.2012.02.034_b0120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/089686080002000631","article-title":"Human peritoneal mesothelial cells produce nitric oxide: induction by cytokines","volume":"20","author":"Chen","year":"2000","journal-title":"Perit. Dial. Int."},{"key":"10.1016\/j.canlet.2012.02.034_b0125","first-page":"410","article-title":"Chronic inflammation and cancer: the role of the mitochondria","volume":"25","author":"Kamp","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2012.02.034_b0130","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","article-title":"Oxidative stress, inflammation, and cancer: how are they linked?","volume":"49","author":"Reuter","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0748233710374464","article-title":"Cyto-genotoxicity of amphibole asbestos fibers in cultured human lung epithelial cell line: role of surface iron","volume":"26","author":"Srivastava","year":"2010","journal-title":"Toxicol. Indust. Health"},{"key":"10.1016\/j.canlet.2012.02.034_b0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00204-004-0608-6","article-title":"Production of nitric oxide elevates nitrosothiol formation resulting in decreased glutathione in macrophages exposed to asbestos or asbestos substitutes","volume":"79","author":"Nishiike","year":"2005","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.canlet.2012.02.034_b0145","first-page":"178","article-title":"Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma","volume":"31","author":"Haslam","year":"1978","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0002-9343(79)90408-X","article-title":"Asbestos-associated neoplasms of B cell lineage","volume":"67","author":"Kagan","year":"1979","journal-title":"Am. J. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0155","first-page":"426","article-title":"Acute injury and regeneration of the mesothelium in response to asbestos fibers","volume":"128","author":"Moalli","year":"1987","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0891-5849(94)90140-6","article-title":"Cytotoxicity of oxidants and asbestos fibers in cultured human mesothelial cells","volume":"16","author":"Kinnula","year":"1994","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1383-5718(00)00053-X","article-title":"Levels of 8-hydroxy-2X-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany","volume":"468","author":"Marczynski","year":"2000","journal-title":"Mutat. Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.biocel.2003.09.007","article-title":"Behaviour of the new asbestos amphibole fluoro-edenite in different lung cell systems","volume":"36","author":"Cardile","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0175","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.02.034_b0180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1183\/09031936.03.00403902","article-title":"Immunological mechanisms in pleural disease","volume":"21","author":"Antony","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.canlet.2012.02.034_b0185","first-page":"1289","article-title":"Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: the role of Toll-like receptor 4","volume":"15","author":"Kato","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.canlet.2012.02.034_b0190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4049\/jimmunol.179.1.514","article-title":"Nod1\/RICK and TLR signaling regulate chemokine and antimicrobial innate immune responses in mesothelial cells","volume":"179","author":"Park","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0195","doi-asserted-by":"crossref","first-page":"L461","DOI":"10.1152\/ajplung.00276.2007","article-title":"Innate immune responses in murine pleural mesothelial cells: Toll-like receptor-2 dependent induction of beta-defensin-2 by staphylococcal peptidoglycan","volume":"295","author":"Hussain","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.canlet.2012.02.034_b0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00011-009-0012-z","article-title":"Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells","volume":"58","author":"Wu","year":"2009","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cellbi.2008.10.011","article-title":"Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma","volume":"33","author":"W\u00f6rnle","year":"2009","journal-title":"Cell. Biol. Int."},{"key":"10.1016\/j.canlet.2012.02.034_b0210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11010-008-9957-4","article-title":"Novel role of Toll-like receptor 3, RIG-I and MDA5 in poly (I:C) RNA-induced mesothelial inflammation","volume":"322","author":"W\u00f6rnle","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.canlet.2012.02.034_b0975","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1160\/TH08-11-0744","article-title":"Role of viral receptors TLR3, RIG-I and MDA5 in mesothelial tissue-type plasminogen activator and plasminogen activator inhibitor-1 synthesis","volume":"101","author":"W\u00f6rnle","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.canlet.2012.02.034_b0220","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.matbio.2009.12.002","article-title":"Effect of activation of viral receptors on the gelatinases MMP-2 and MMP-9 in human mesothelial cells","volume":"29","author":"Merkle","year":"2010","journal-title":"Matrix Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0225","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1093\/ndt\/gfr217","article-title":"Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors","volume":"26","author":"Colmont","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.canlet.2012.02.034_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2012.02.034_b0235","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1038\/sj.onc.1201870","article-title":"Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression","volume":"16","author":"Frizelle","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.02.034_b0240","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/sj.cgt.7700241","article-title":"Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus","volume":"7","author":"Frizelle","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0245","first-page":"5547","article-title":"P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0250","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2012.02.034_b0255","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1073\/pnas.0808816106","article-title":"Activated TNF-alpha\/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice","volume":"106","author":"Altomare","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.02.034_b0260","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0265","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.02.034_b0270","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","article-title":"Membrane organization, tumorigenesis-the NF2 tumor suppressor, Merlin","volume":"19","author":"McClatchey","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2012.02.034_b0275","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature04856","article-title":"Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase","volume":"442","author":"Jin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2012.02.034_b0980","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/carcin\/bgn200","article-title":"YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation","volume":"29","author":"Yokoyama","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2012.02.034_b0285","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor NF2, encoding Merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0295","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0300","first-page":"2085","article-title":"Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-Lcysteine in mesothelial cells","volume":"55","author":"Janssen","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0305","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1158\/0008-5472.CAN-04-0946","article-title":"The duration of nuclear extracellular signal-regulated kinase 1 and 2 signaling during cell cycle reentry distinguishes proliferation from apoptosis in response to asbestos","volume":"64","author":"Yuan","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0310","first-page":"3539","article-title":"Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma","volume":"63","author":"Ramos-Nino","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0315","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genomic events associated with progression of pleural malignant mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0320","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/0046-8177(95)90302-X","article-title":"The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas","volume":"26","author":"Peralta Soler","year":"1995","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0985","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Cancer and Leukemia Group B (CALGB 30101), Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0330","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated Red in Translation 137 protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0335","first-page":"4169","article-title":"A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression","volume":"62","author":"Manning","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0340","first-page":"333","article-title":"Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers","volume":"152","author":"Pache","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0345","first-page":"181","article-title":"Activation of the PI3K-AKT pathway in human malignant mesothelioma cells","volume":"2","author":"Suzuki","year":"2009","journal-title":"Mol. Med. Report"},{"key":"10.1016\/j.canlet.2012.02.034_b0350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2007.08.035","article-title":"Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient\u2019s follow-up","volume":"59","author":"Destro","year":"2008","journal-title":"Lung. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0355","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14796694.1.1.79","article-title":"3p21.3 tumor suppressor cluster: prospects for translational applications","volume":"1","author":"Ji","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0360","first-page":"543","article-title":"Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages","volume":"34","author":"Izzi","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0365","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(19920815)70:4<854::AID-CNCR2820700422>3.0.CO;2-#","article-title":"Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity","volume":"70","author":"Martinet","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0370","first-page":"1327","article-title":"Evaluation of inflammatory cytokines in malignant and benign pleural effusions","volume":"7","author":"Alexandrakis","year":"2000","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2012.02.034_b0375","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj3260377","article-title":"Identification of human complement factor H as a chemotactic protein for monocytes","volume":"326","author":"Nabil","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2012.02.034_b0380","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12307-010-0048-1","article-title":"Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma","volume":"4","author":"Miselis","year":"2011","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.canlet.2012.02.034_b0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/imt.10.84","article-title":"Defining the mechanisms of CD8 T-cell tumor tolerance","volume":"3","author":"Kennedy","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2012.02.034_b0390","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","article-title":"Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0395","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.intimp.2011.01.003","article-title":"Myeloid derived suppressor cells in human diseases","volume":"11","author":"Greten","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2012.02.034_b0400","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/eji.200939486","article-title":"Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development","volume":"39","author":"Greifenberg","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0405","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma, Celecoxib influences MDSC function","volume":"30","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0410","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","article-title":"IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients","volume":"182","author":"Mandruzzato","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0415","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2119\/molmed.2010.00178","article-title":"A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma","volume":"17","author":"Cuenca","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0420","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1158\/1078-0432.CCR-07-0182","article-title":"Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy","volume":"13","author":"Talmadge","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0425","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0430","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"TRENDS Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0435","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0440","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1567-5769(02)00064-4","article-title":"Tumor-associated macrophages: a molecular perspective","volume":"2","author":"Sica","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2012.02.034_b0445","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01534421","article-title":"Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model","volume":"39","author":"Bielefeldt-Ohmann","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0450","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.canlet.2012.02.034_b0455","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1535-7163.MCT-07-0579","article-title":"Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma","volume":"7","author":"Miselis","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0460","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"Veltman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0465","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1164\/ajrccm\/139.6.1369","article-title":"Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells","volume":"139","author":"Manning","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.canlet.2012.02.034_b0470","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1993.3","article-title":"An analysis of the relationship between \u03b3\u03b4 T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity","volume":"71","author":"Mavaddat","year":"1993","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0475","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<740::AID-IJC12>3.0.CO;2-5","article-title":"Primary human mesothelioma cells express class II MHC, ICAM-1 and B7\u20132 and can present recall antigens to autologous blood lymphocytes","volume":"78","author":"Mutti","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0480","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00101008","article-title":"Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells","volume":"34","author":"Jackaman","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.canlet.2012.02.034_b0485","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0490","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.178.7.4089","article-title":"Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells","volume":"178","author":"Rudge","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0495","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.canlet.2012.02.034_b0500","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00262-008-0628-9","article-title":"Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy","volume":"58","author":"van der Most","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0505","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/039463200902200106","article-title":"CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma","volume":"22","author":"Shimizu","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.canlet.2012.02.034_b0510","doi-asserted-by":"crossref","DOI":"10.1097\/JTO.0b013e3182208ee0","article-title":"Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model","author":"Wu","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0515","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"Ho","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0520","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1349-7006.2009.01181.x","article-title":"Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers","volume":"100","author":"Shigematsu","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2012.02.034_b0525","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1165\/ajrcmb.22.5.3930","article-title":"Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities","volume":"22","author":"Robinson","year":"2000","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0530","first-page":"261","article-title":"Immunological effects of silica and asbestos","volume":"4","author":"Otsuki","year":"2007","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0535","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17843286.1989.11718015","article-title":"Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma","volume":"44","author":"Selleslag","year":"1989","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.canlet.2012.02.034_b0540","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/107602960401000413","article-title":"Antiphospholipid syndrome associated with malignant mesothelioma presenting with superior vena cava thrombosis: a case report","volume":"10","author":"Ozkan","year":"2004","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.canlet.2012.02.034_b0545","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.imlet.2004.11.005","article-title":"Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos\/chrysotile-A","volume":"98","author":"Wu","year":"2005","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.canlet.2012.02.034_b0550","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic analysis of exosomes isolated from human malignant pleural effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0555","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63739-X","article-title":"Proteomic analysis of exosomes secreted by human mesothelioma cells","volume":"164","author":"Hegmans","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0560","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1158\/0008-5472.CAN-06-3456","article-title":"Human tumor-derived exosomes selectively impair lymphocyte responses to Interleukin-2","volume":"67","author":"Clayton","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0565","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2005.03.003","article-title":"Exosomes and the MICA-NKG2D system in cancer","volume":"34","author":"Clayton","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.canlet.2012.02.034_b0570","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4049\/jimmunol.1003884","article-title":"Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production","volume":"187","author":"Clayton","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0575","first-page":"121","article-title":"Drug delivery systems for antitumor activation of macrophages","volume":"7","author":"Tabata","year":"1990","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.canlet.2012.02.034_b0580","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ijc.2910150212","article-title":"BCG therapy of pleural and peritoneal growth of transplanted rat tumours","volume":"15","author":"Pimm","year":"1975","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0585","first-page":"277","article-title":"Immunotherapy with BCG vaccine in 30 cases of mesothelioma","volume":"61","author":"Webster","year":"1982","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.canlet.2012.02.034_b0590","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1054\/bjoc.2000.1401","article-title":"A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma","volume":"83","author":"O\u2019Brien","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0595","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1365-2133.2001.04117.x","article-title":"Cutaneous toxicity after intradermal vaccination with Mycobacterium vaccae against lung cancer and malignant mesothelioma","volume":"144","author":"Pandha","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.canlet.2012.02.034_b0600","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.bjc.6600063","article-title":"Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma","volume":"86","author":"Mendes","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0605","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000226571","article-title":"Intrapleural natural beta interferon in the treatment of malignant pleural effusions","volume":"45","author":"Rosso","year":"1988","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2012.02.034_b0610","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00001813-199502000-00009","article-title":"Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines","volume":"6","author":"Hand","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canlet.2012.02.034_b0615","first-page":"3298","article-title":"Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma","volume":"8","author":"Gattacceca","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0620","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study","volume":"121","author":"Monnet","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.canlet.2012.02.034_b0625","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0630","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0635","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene. Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0640","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/030089169207800211","article-title":"Intracavitary administration of Interleukin-2 as palliative therapy for neoplastic effusions","volume":"30","author":"Lissoni","year":"1992","journal-title":"Tumori"},{"key":"10.1016\/j.canlet.2012.02.034_b0645","first-page":"489","article-title":"Effects of Interleukin-2 for the treatment of malignant mesothelioma","volume":"5","author":"Nano","year":"1998","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2012.02.034_b0650","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of Interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0655","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0660","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6605438","article-title":"Treatment with Interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact","volume":"101","author":"Al\u00ec","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0665","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/oxfordjournals.annonc.a058941","article-title":"A phase II trial of dose-escalated doxorubicin and ifosfamide\/mesna in patients with malignant mesothelioma","volume":"5","author":"Dirix","year":"1994","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0670","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00002371-199809000-00007","article-title":"Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma","volume":"21","author":"Davidson","year":"1998","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0675","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijc.20574","article-title":"Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte\/macrophage colony stimulating factor in mesothelioma","volume":"113","author":"Triozzi","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0680","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10147-004-0432-2","article-title":"Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma with the expression of other cytokines","volume":"10","author":"Yoshimoto","year":"2005","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0685","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2006.01.007","article-title":"Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma","volume":"52","author":"Powell","year":"2006","journal-title":"Lung. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0690","first-page":"321","article-title":"Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression","volume":"3","author":"Leong","year":"1996","journal-title":"Cancer Gene. Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0695","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<476::AID-IJC28>3.0.CO;2-C","article-title":"Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma","volume":"71","author":"Leong","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0700","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.cji.0000187958.38179.a9","article-title":"Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides","volume":"29","author":"van der Most","year":"2006","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0705","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/JTO.0b013e3181a8634d","article-title":"Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA","volume":"4","author":"Stone","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0710","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.4049\/jimmunol.0803826","article-title":"Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy","volume":"182","author":"Broomfield","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2012.02.034_b0715","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1099\/0022-1317-28-2-225","article-title":"Immunomodification and the expression of virulence in mice by defined strains of semliki forest virus: the effects of cyclophosphamide","volume":"28","author":"Bradish","year":"1975","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.canlet.2012.02.034_b0720","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1476-5586(03)80010-6","article-title":"Differential uptake of (18)F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification","volume":"5","author":"Mamede","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2012.02.034_b0725","first-page":"377","article-title":"Local adoptive immunotherapy using lymphokine-activated killer cells and Interleukin-2 against malignant pleural mesothelioma: report of two cases","volume":"21","author":"Yanagawa","year":"1991","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0730","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s005950050200","article-title":"Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases","volume":"28","author":"Tani","year":"1998","journal-title":"Surg. Today"},{"key":"10.1016\/j.canlet.2012.02.034_b0735","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0740","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/icb.2010.88","article-title":"CD40-activated B cells contribute to mesothelioma tumor regression","volume":"89","author":"Jackaman","year":"2011","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0745","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0750","first-page":"245","article-title":"Considerations on clinical use of T cell immunotherapy for cancer","volume":"51","author":"Plautz","year":"2003","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.canlet.2012.02.034_b0755","doi-asserted-by":"crossref","first-page":"11752","DOI":"10.1158\/0008-5472.CAN-05-1658","article-title":"Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma","volume":"65","author":"Jassar","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0760","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.2910570117","article-title":"Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line","volume":"57","author":"Chang","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0765","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.02.034_b0990","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0775","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1158\/1078-0432.CCR-05-0596","article-title":"Identification of novel human CTL epitopes and their agonist epitopes of mesothelin","volume":"11","author":"Yokokawa","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0780","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.2741\/Jasani","article-title":"Simian virus 40 detection in human mesothelioma: reliability and significance of the available molecular evidence","volume":"6","author":"Jasani","year":"2001","journal-title":"Front. Biosci."},{"key":"10.1016\/j.canlet.2012.02.034_b0785","first-page":"109","article-title":"Polio vaccines, SV40 and human tumours, an update on false positive and false negative results","volume":"123","author":"Elmishad","year":"2006","journal-title":"Dev. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0790","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jnci\/91.2.169","article-title":"Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen","volume":"91","author":"Xie","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2012.02.034_b0795","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00262-001-0240-8","article-title":"SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients","volume":"50","author":"Bright","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0800","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/ng0893-415","article-title":"The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma","volume":"4","author":"Park","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2012.02.034_b0805","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.5858\/2005-129-1407-IDOEMA","article-title":"Immunohistochemical diagnosis of epithelioid mesothelioma: an update","volume":"129","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0810","doi-asserted-by":"crossref","first-page":"102758","DOI":"10.1155\/2010\/102758","article-title":"TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy","volume":"2010","author":"Bei","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.canlet.2012.02.034_b0815","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms\u2019 tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0820","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0825","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/092986708783955446","article-title":"Molecular targets and targeted therapies for malignant mesothelioma","volume":"15","author":"Palumbo","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.canlet.2012.02.034_b0830","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/sonc.2002.30234","article-title":"New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents","volume":"29","author":"Nowak","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2012.02.034_b0835","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.gt.3302974","article-title":"Control of human mesothelin-expressing tumors by DNA vaccines","volume":"14","author":"Chang","year":"2007","journal-title":"Gene. Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0840","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.cgt.7700347","article-title":"The immune anti-tumor effects of GM-CSF and B7\u20131 gene transfection are enhanced by surgical debulking of tumor","volume":"8","author":"Mukherjee","year":"2001","journal-title":"Cancer Gene. Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0845","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0264-410X(02)00600-X","article-title":"Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia","volume":"21","author":"Gr\u00e9goire","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2012.02.034_b0850","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1164\/rccm.200312-1683OC","article-title":"Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells","volume":"169","author":"Ebstein","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0855","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2559.2005.02331.x","article-title":"Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data","volume":"48","author":"King","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2012.02.034_b0860","first-page":"5228","article-title":"Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential","volume":"48","author":"Hsu","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0865","first-page":"1031","article-title":"Intraperitoneal immunoconjugates","volume":"50","author":"Griffin","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0870","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00002371-199201000-00002","article-title":"Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies","volume":"11","author":"Griffin","year":"1992","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2012.02.034_b0875","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000478-199203000-00006","article-title":"Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma","volume":"16","author":"Chang","year":"1992","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2012.02.034_b0880","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<638::AID-IJC21>3.0.CO;2-6","article-title":"Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers","volume":"71","author":"Brinkmann","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0885","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.02.034_b0890","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1006\/jmbi.1998.1980","article-title":"Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv","volume":"281","author":"Chowdhury","year":"1998","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.02.034_b0895","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"10.1016\/j.canlet.2012.02.034_b0900","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0905","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","article-title":"A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity","volume":"8","author":"Feng","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0910","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"Ho","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0915","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1349-7006.2009.01463.x","article-title":"Antitumor activity of anti-C-ERC\/mesothelin monoclonal antibody in vivo","volume":"101","author":"Inami","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2012.02.034_b0920","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"Chowdhury","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2012.02.034_b0925","first-page":"1201","article-title":"Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein","volume":"46","author":"Sato","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2012.02.034_b0930","first-page":"79","article-title":"Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer","volume":"1","author":"Bera","year":"2001","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2012.02.034_b0935","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1749-6632.2009.04933.x","article-title":"The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205\/CD205 receptor on dendritic cells","volume":"1174","author":"Wang","year":"2009","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2012.02.034_b0940","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1101\/gad.14.15.1837","article-title":"Wnt signaling and cancer","volume":"14","author":"Polakis","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2012.02.034_b0945","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1476-5586(04)80048-4","article-title":"A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells","volume":"6","author":"He","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2012.02.034_b0950","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ijc.21160","article-title":"Wnt2 as a new therapeutic target in malignant pleural mesothelioma","volume":"117","author":"Mazieres","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2012.02.034_b0955","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","article-title":"Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.02.034_b0960","doi-asserted-by":"crossref","unstructured":"V. Gregorc, G.L. Ceresoli, P.A. Zucali, F.G. De Braud, E. Bajetta, A. Santoro, M.G. Vigan\u00f2, F. Caligaris Cappio, A. Lambiase, C. Bordignon, Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in: Previously Treated Patients with Malignant Pleural Mesothelioma (MPM), ASCO Abstract # 7582.","DOI":"10.1200\/jco.2009.27.15_suppl.7582"},{"key":"10.1016\/j.canlet.2012.02.034_b0965","doi-asserted-by":"crossref","unstructured":"V. Gregorc, G.L. Ceresoli, P.A. Zucali, V. Gregorc, G.L. Ceresoli, P.A. Zucali, F.G. De Braud, E. Bajetta, A. Santoro, M.G. Vigan\u00f2, F. Caligaris Cappio, A. Lambiase, C. Bordignon, NGR-hTNF, a vascular targeting agent (VTA), in: Previously Treated Patients with Malignant Pleural Mesothelioma (MPM): A Phase II Study, ECCO 15\u201334th ESMO 2009 \u2013 Abstract # 9011.","DOI":"10.1016\/S1359-6349(09)71724-0"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512001450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512001450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T18:48:00Z","timestamp":1687286880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383512001450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":193,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0304383512001450"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2012.02.034","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}